AlphaBiolabs invests over £3 million to provide next-generation genome sequencing and 24-hour UKAS-audited PCR testing to meet increased demand

Press Release: 1st June 2021

AlphaBiolabs invests over £3 million to provide next-generation genome sequencing

AlphaBiolabs is one of the first UK laboratories to be successfully audited by UKAS for Covid-19 testing. It has also recently invested in the latest genome sequencing technology, making it one of only a handful of labs in the UK to offer this crucial service.

The award-winning company has also ramped up its operations to meet the increased demand for Covid-19 testing, employing an additional 68 people since the start of the year across laboratory, logistics and customer service roles.

The Warrington-based firm provides rapid Covid-19 PCR testing for members of the public and third-party companies that are providing PCR testing to their own customers. It also provides comprehensive workplace testing programmes for businesses, helping to keep the workplace safe and also supporting with essential travel requirements.

Rachel Davenport, Director of AlphaBiolabs, said that reporting results quickly and accurately has been key to the firm’s recent success.

“All testing is performed in AlphaBiolabs’ purpose-designed UK laboratory. In addition, the business has invested in its own next-generation genome sequencing service to identify any new variants. As well as enabling rapid sample turnaround and same-day results, this is vital for detecting and isolating new variants of the SARS CoV 2 virus as it mutates.”

PCR testing is classed as the gold standard in Covid-19 testing. It involves taking swab samples from the nose and throat, which are then returned to the laboratory for analysis.

Casey Randall, Head of Covid-19 Testing at AlphaBiolabs, commented: “As one of the government’s listed testing providers, we’re held to the very highest of standards. A recently successful UKAS audit highlights the accuracy and reliability across our laboratory testing services and we expect our UKAS accreditation schedule to be updated before the end of June.”

Rachel added that combining the successful audit with competitive pricing, genome sequencing and 24-hour results puts AlphaBiolabs in an especially strong position to support businesses with their Covid-19 testing requirements.

“As we gradually move out of lockdown and more people start to return to work, we have seen a significant increase in the demand for our workplace testing services.

“There is clearly a real commitment among employers to keep Covid-19 out of the workplace as businesses across the UK try to navigate and manage their operations in a proactive manner. Employers are understandably looking at effective testing programmes to protect both their business and their workforce.”

Notes to editors

AlphaBiolabs provides DNA, drug and alcohol testing services to a client base which includes members of the public, businesses, family and immigration law solicitors, social services, the media and universities. The company, founded in 2004, is based in Warrington, where it has one of the largest laboratories of its kind in Europe.

It was the first UKAS ISO 17025 accredited laboratory to introduce a next-day DNA testing service, which helped earn AlphaBiolabs a Queen’s Award for Innovation in 2016. The laboratory has also developed state-of-the-art techniques to provide an accurate historical record of drug or alcohol abuse. Hair strands, oral fluids, urine and fingernails can all be tested. It also offers continuous alcohol monitoring with its SCRAM CAM alcohol-testing bracelet.

AlphaBiolabs has walk-in centres in north and south London, Birmingham, Cardiff, Leeds, Liverpool, Manchester, Glasgow, Newcastle upon Tyne, Preston and Warrington.

Visit for more information.

The media contact for AlphaBiolabs is Alyssa James

Email: or
Phone: 01925 255450